Jiangsu Hengrui Medicine was granted CFDA approval to start clinical trials of SHR-1314, an injected drug aimed at treating autoimmune diseases. Hengrui will initially test the drug in psoriasis patients. The drug is an independently developed humanized mAb that targets IL-17A and hinders signal transduction, reducing the inflammatory response. Hengrui filed for the approval two years ago with the Jiangsu Province FDA.
